Azathioprine: State of the art in inflammatory bowel disease

Scandinavian Journal of Gastroenterology, Supplement

Volumn 33, Issue 225 SUPPL., 1998, Pages 92-99

  Sandborn, W J ^a  

^a MAYO CLINIC   (United States)

Author keywords

6 Mercaptopurine; Azathioprine; Crohn's disease; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; CONFERENCE PAPER; CROHN DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; ENTERITIS; ERYTHROCYTE; FEVER; HEPATITIS; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAINTENANCE THERAPY; MALAISE; NAUSEA; ORAL DRUG ADMINISTRATION; PANCREATITIS; PRIORITY JOURNAL; RASH; REMISSION; THROMBOCYTOPENIA; TIME; ULCERATIVE COLITIS; BLOOD; HALF LIFE TIME; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK;

6-MERCAPTOPURINE; AZATHIOPRINE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS;

EID: 0037717938     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
2. Personal communication R. England, Glaxo Wellcome, Middlesex, UK.
3. Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996;39:63-8.
4. Amdt CAS, Balis FM, McCully CL, Jeffries SL, Doherty K, Murphy R, et al. Bioavailability of low-dose vs high-dose 6-mercaptopurine. Clin Pharmacol Ther 1988;43:588-91.
5. Chan GLC, Erdman GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol l990;30:358-63.
6. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics; monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
7. Leonard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
8. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7.
9. Pearson DC, May GR, Pick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995;123:132-42.
10. Rhodes J, Bainton D, Beck P, Cambell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971(7737);2:1273-6.
11. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974;66:916-22.
12. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.